Analyst Ratings For Tandem Diabetes Care Inc (NASDAQ:TNDM)
Today, Oppenheimer set its price target on Tandem Diabetes Care Inc (NASDAQ:TNDM) to $31.00 per share.
There are 8 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Tandem Diabetes Care Inc (NASDAQ:TNDM) is Buy with a consensus target price of $25.3889 per share, a potential 3.90% downside.
Some recent analyst ratings include
- 7/31/2018-Stifel Nicolaus Reiterated Rating of Hold .
- 7/31/2018-Cowen Reiterated Rating of Buy.
- 7/23/2018-Robert W. Baird Reiterated Rating of Buy.
Recent Insider Trading Activity For Tandem Diabetes Care Inc (NASDAQ:TNDM)
Tandem Diabetes Care Inc (NASDAQ:TNDM) has insider ownership of 9.30% and institutional ownership of 50.79%.
- On 3/6/2018 Dick Allen, Director, bought 25,539 with an average share price of $3.88 per share and the total transaction amounting to $99,091.32.
- On 2/9/2018 Christopher J Twomey, Director, bought 75,000 with an average share price of $2.00 per share and the total transaction amounting to $150,000.00.
- On 2/9/2018 Kim D Blickenstaff, CEO, bought 750,000 with an average share price of $2.00 per share and the total transaction amounting to $1,500,000.00.
- On 10/13/2017 Kim D Blickenstaff, CEO, bought 285,700 with an average share price of $3.50 per share and the total transaction amounting to $999,950.00.
- On 3/23/2017 Kim D Blickenstaff, CEO, bought 1,600,000 with an average share price of $1.25 per share and the total transaction amounting to $2,000,000.00.
- On 8/1/2016 John F Sheridan, EVP, sold 15,000 with an average share price of $6.52 per share and the total transaction amounting to $97,800.00.
- On 5/2/2016 John F Sheridan, COO, sold 2,000 with an average share price of $10.61 per share and the total transaction amounting to $21,220.00.
About Tandem Diabetes Care Inc (NASDAQ:TNDM)
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; t:slim X2 with G5 integration; and Tandem Device Updater, a PC and Mac-compatible tool that allows users to update their pump's software. In addition, the company offers t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; t:lock cartridge and infusion set products; and various pump accessories. Its products in development include automated insulin delivery systems; t:slim X2 with Basal IQ; t:slim X2 with control IQ; t:sport insulin delivery system; and connected (mobile) health mobile application. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.
Recent Trading Activity for Tandem Diabetes Care Inc (NASDAQ:TNDM)
Shares of Tandem Diabetes Care Inc closed the previous trading session at 26,70 up +1,86 7,49 % with 26.84 shares trading hands.